01:53 AM EDT, 07/13/2026 (MT Newswires) -- Prolight Diagnostics (PRLD.ST) said Monday it entered into a development agreement with medical technology platform BrainBox Solutions. The deal followed a 260-patient feasibility study and covers the development of multiplex cartridges, software, and the initial purchase of pilot instruments for the BrainBox system, which utilizes Prolight's Psyros platform with three assays for traumatic brain injury. The system is under US Food and Drug Administration review and Prolight said regulatory approval of the BrainBox system would also mark US market clearance for its Psyros platform. The innovative point-of-care systems developer expects to generate 2.2 million pounds sterling in total revenue from the deal.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.